You are here

Cordlife partners US-Based PlumCare to offer genetic screening service

MAINBOARD-listed healthcare company, Cordlife Group, has entered into a partnership with PlumCare, a US-based company, to offer a genetic testing service to help families in Asia identify gene variants associated with increased risk of developing inherited conditions such as breast and ovarian cancer.

"PlumCare™ DNA Advisor is the brainchild of Petros Tsipouras, a specialist in clinical genetics and an adjunct professor at Yale University School of Medicine, and Paul Billings, a specialist in genomic medicine. The team at PlumCare is also made up of highly experienced scientific and medical informatics specialists associated with Harvard and Yale Universities," Cordlife said.

It cited a recent study saying that the global DNA testing market is estimated to reach US$10.04 billion by 2022. In the Asia-Pacific region, the industry is anticipated to witness high growth due to developments in healthcare infrastructure, coupled with a large target population suffering from chronic and acute conditions.

Cordlife will soon launch and market the PlumCare™ DNA Advisor under the Genscreen brand. Other diagnostics services in its portfolio include non-invasive prenatal testing, urine-based metabolic screening for newborns, and paediatric vision screening for children aged six months to six years.

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes